| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/22/2009 | US20090022802 Cardiomyopathy therapeutic agent |
| 01/22/2009 | US20090022801 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms |
| 01/22/2009 | US20090022800 Coating for small bodies |
| 01/22/2009 | US20090022799 Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use |
| 01/22/2009 | US20090022798 Formulations of nonopioid and confined opioid analgesics |
| 01/22/2009 | US20090022797 Stabilized tolterodine tartrate formulations |
| 01/22/2009 | US20090022796 Novel Substituted Benzimidazole Dosage Forms and Method of Using Same |
| 01/22/2009 | US20090022795 Stable Pharmaceutical Formulation of an Acid Labile Compound and Process for Preparing the Same |
| 01/22/2009 | US20090022794 Topiramate Tablet Formulation |
| 01/22/2009 | US20090022793 Mesalamine suppository |
| 01/22/2009 | US20090022792 Vitamin D content uniformity in pharmaceutical dosage forms |
| 01/22/2009 | US20090022791 Porous cellulose aggregate and molding composition thereof |
| 01/22/2009 | US20090022790 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 01/22/2009 | US20090022789 Enhanced formulations of lamotrigine |
| 01/22/2009 | US20090022788 Dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers |
| 01/22/2009 | US20090022787 Pharmaceutical composition comprising 11-deoxy- prostaglandin compound and method for stabilizing the compound |
| 01/22/2009 | US20090022786 Oral pharmaceutical dosage form and manufacturing method thereof |
| 01/22/2009 | US20090022785 Permeable Capsules |
| 01/22/2009 | US20090022784 Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin |
| 01/22/2009 | US20090022783 siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES |
| 01/22/2009 | US20090022782 Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| 01/22/2009 | US20090022780 Hydrogel |
| 01/22/2009 | US20090022777 Methods for progenitor cell recruitment and isolation |
| 01/22/2009 | US20090022776 Composition and method for treatment and prevention of restenosis |
| 01/22/2009 | US20090022772 Bioabsorbable elastomeric arterial support device and methods of use |
| 01/22/2009 | US20090022769 Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients |
| 01/22/2009 | US20090022768 Continuous flow chamber device for separation, concentration, and/or purification of cells |
| 01/22/2009 | US20090022683 Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof |
| 01/22/2009 | US20090022671 Treatment methods |
| 01/22/2009 | US20090022670 Novel compounds |
| 01/22/2009 | US20090022669 Compositions for protein delivery via the pulmonary route |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | US20090022655 boron neutron capture therapy, attaching antibody (IgG) cell-targeting species to BN nanostructures to form composite, administering to target tumors, activating boron in composite; indirect source of radiation therapy, delivery vehicles for radio- and chemo-therapeutic materials, imaging agents |
| 01/22/2009 | CA2730841A1 Osteopontin nanoparticle system for drug delivery |
| 01/22/2009 | CA2695952A1 Micro-particles, blood-substitute and method for forming same |
| 01/22/2009 | CA2694620A1 Solid preparation comprising alogliptin and metformin hydrochloride |
| 01/22/2009 | CA2694089A1 Therapeutic stable nanoparticles |
| 01/22/2009 | CA2693577A1 Dry-powder medicament |
| 01/22/2009 | CA2693219A1 Compositions and methods for wound healing |
| 01/22/2009 | CA2691995A1 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
| 01/22/2009 | CA2691002A1 Self-assembling amphiphilic polymers as anticancer agents |
| 01/21/2009 | EP2017331A1 Method of producing s-adenosyl-l-methionine-containing dry yeast having excellent storage stability, the product thereof and composition for oral intake |
| 01/21/2009 | EP2017287A2 Method of producing hydroxyalkyl starch derivatives |
| 01/21/2009 | EP2017251A1 Method for stabilization of reduced coenzyme q10 |
| 01/21/2009 | EP2017191A1 Edible film package having product for oral intake enclosed therein |
| 01/21/2009 | EP2016942A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 01/21/2009 | EP2016941A1 Transdermally absorbable donepezil preparation |
| 01/21/2009 | EP2016940A1 Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| 01/21/2009 | EP2016939A1 Transdermally absorbable preparation comprising anti-dementia agent |
| 01/21/2009 | EP2016938A1 Preparation of submicron sized particles via dispersion and solevnt or liquid phase removal |
| 01/21/2009 | EP2016937A1 Formulation of liposomal vesicles in aqueous solutions with tear film characteristics |
| 01/21/2009 | EP2016936A1 Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
| 01/21/2009 | EP2016935A1 Pharmaceutical composition for topical application of poorly soluble compounds |
| 01/21/2009 | EP2016898A2 Ingestible device for the release of substances at distinct locations in the alimentary canal |
| 01/21/2009 | EP2015805A1 Osmotic pump with at least one chargeable material |
| 01/21/2009 | EP2015779A2 Transmucosal composition |
| 01/21/2009 | EP2015737A1 A process of preparing microspheres for sustained release having improved dispersibility and syringeability |
| 01/21/2009 | EP2015736A2 Spherical or non-sperical microcapsules comprising glp-1 peptides, their production and use |
| 01/21/2009 | EP2015735A1 Tolterodine beads |
| 01/21/2009 | EP2015734A2 Solid dosage formulations |
| 01/21/2009 | EP2015733A2 Compositions for the treatment and prevention of eyelid swelling |
| 01/21/2009 | EP2015732A2 Heated roller compaction process for making pharmaceutical compositions |
| 01/21/2009 | EP2015731A2 Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| 01/21/2009 | EP2015730A1 Method for solubilising hydrophobic active substances in an aqueous medium |
| 01/21/2009 | EP2015729A2 Improved storage stable one component polyurethane system |
| 01/21/2009 | EP2015728A2 Liquid pharmaceutical formulation |
| 01/21/2009 | EP2015632A2 Stable hydroalcoholic oral spray formulations and methods |
| 01/21/2009 | EP1845777A4 Starch derivatives and other derivatives, production processes therefor, and wound healing applications therefor |
| 01/21/2009 | EP1660034B1 Manufacture of long term drug delivery devices with polyurethane based polymers |
| 01/21/2009 | EP1590004B1 Process for the production of improved thickened beverages for dysphagia |
| 01/21/2009 | EP1513500B1 Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with pradofloxacin and intrinsically viscous gelling agents as thickening agents |
| 01/21/2009 | EP1497323B1 Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein |
| 01/21/2009 | EP1347741B1 Sustained release drug delivery devices with multiple agents |
| 01/21/2009 | EP1133316B1 Formulation of adenovirus for gene therapy |
| 01/21/2009 | EP1129209B1 Polymer grafting by polysaccharide synthases |
| 01/21/2009 | EP0973507B1 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| 01/21/2009 | EP0946155B2 Pharmaceutical composition for treating fecal incontinence |
| 01/21/2009 | EP0711127B2 Methods of preparing gas-filled liposomes |
| 01/21/2009 | CN101351227A Pharmaceutical composition for application to nail |
| 01/21/2009 | CN101351201A Pharmaceutical preparation of aqueous solution containing platinum complex |
| 01/21/2009 | CN101351199A Composition for soft contact lens and adsorption suppressing method |
| 01/21/2009 | CN101351197A Encapsulated chromonic particles |
| 01/21/2009 | CN101351196A Lipophilic vehicle-based dual controlled release matrix system |
| 01/21/2009 | CN101351195A Sectionalised medicament dose form |
| 01/21/2009 | CN101351194A Pack |
| 01/21/2009 | CN101351193A Dry formulations of aripiprazole |
| 01/21/2009 | CN101351192A Wet granulation method for preparing pharmaceutical compositions of aripiprazole |
| 01/21/2009 | CN101351191A Fenofibrate medicinal preparation with improved bioavailability |
| 01/21/2009 | CN101351190A Sodium chloride solution for drug reconstitution or dilution |
| 01/21/2009 | CN101351189A Pharmaceutical composition for the treatment of nail diseases |
| 01/21/2009 | CN101351188A Estrogen compositions and therapeutic methods of use thereof |
| 01/21/2009 | CN101351181A Skin patch and method of producing the same |
| 01/21/2009 | CN101351174A Adhesive patch |
| 01/21/2009 | CN101348570A Preparation of star copolymer self-assembled nano micelle |
| 01/21/2009 | CN101348513A Ganoderic acid extraction method and preparation of soft capsule of ganoderic acid |
| 01/21/2009 | CN101348494A High-purity cefmenoxime hydrochloride and preparation thereof |
| 01/21/2009 | CN101348493A High-purity medicament and preparation thereof |
| 01/21/2009 | CN101348492A High-purity ceftizoxime sodium and preparation thereof |
| 01/21/2009 | CN101348431A Method for producing low lead light density granular calcium citrate |
| 01/21/2009 | CN101347622A Oral liquid-crystal sustained-release composition and preparation |